<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03506243</url>
  </required_header>
  <id_info>
    <org_study_id>TG1409CPL</org_study_id>
    <nct_id>NCT03506243</nct_id>
  </id_info>
  <brief_title>Randomized Controlled Study of Comparing Follitrope Versus Gonal-f in Chinese Infertility Women.</brief_title>
  <official_title>A Phase III, Multicenter, Blinded, Randomized, Controlled, Parallel, Comparative Study for the Evaluation of Safety and Efficacy of rhFSH Injection Compared With Gonal-F® Pen Undergoing Controlled Ovarian Hyper Stimulation IVF-ET</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hangzhou YuYuan Bioscience Technology Co., Ltd.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>LG Chem</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hangzhou YuYuan Bioscience Technology Co., Ltd.</source>
  <brief_summary>
    <textblock>
      This study is for evaluating safety and efficacy of Recombinant human follicle-stimulating
      hormone (Follitrope) injection compared with Gonal-F® Pen undergoing controlled ovarian hyper
      stimulation in vitro fertilization - embryo transfer (IVF-ET) in China
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 3, multicenter, blinded, randomized, controlled, parallel, comparative study
      for the evaluation of safety and efficacy of Recombinant human follicle-stimulating hormone
      injection (Follitrope) compared with Gonal-F® Pen undergoing controlled ovarian hyper
      stimulation in vitro fertilization - embryo transfer (IVF-ET) in China.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 2015</start_date>
  <completion_date type="Actual">May 2017</completion_date>
  <primary_completion_date type="Actual">September 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The total number of oocytes retrieved</measure>
    <time_frame>15 days after using FSH</time_frame>
    <description>The total number of oocytes retrieved</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total dose and duration of FSH administration</measure>
    <time_frame>Throughout the study completion (e.g., 10 days)</time_frame>
    <description>Total dose and duration of FSH administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>No. of follicles with diameter equal or more than 14 mm on hGH injection day</measure>
    <time_frame>The day of hGH injection</time_frame>
    <description>No. of follicles with diameter equal or more than 14 mm on hGH injection day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>No. of embryo transferred</measure>
    <time_frame>3 days after the ovum pick-up</time_frame>
    <description>No. of embryo transferred</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical pregnancy rate</measure>
    <time_frame>5 weeks after the embryo transfer</time_frame>
    <description>Clinical pregnancy rate by g-sac</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>On-going pregnancy rate</measure>
    <time_frame>10 weeks after the embryo transfer</time_frame>
    <description>On-going pregnancy rate by fetal heart-beat</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">451</enrollment>
  <condition>Infertility, Female</condition>
  <arm_group>
    <arm_group_label>Test group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Follitrope PFS</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Gonal-F pen</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Follitrope PFS</intervention_name>
    <description>Follitrope PFS</description>
    <arm_group_label>Test group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Gonal-f pen</intervention_name>
    <description>Gonal-f pen</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Infertile adult women between 20 and 39 years at screening.

          2. Infertile adult women with regular menstrual cycles of 25 to 35 days at screening.

          3. Normal basal serum FSH, LH, E2, and P levels at the early follicular phase at
             screening.

          4. If the cause of infertility is due to following reasons:

               -  Tubal factor

               -  Unknown reason

               -  Male infertility

               -  Combined factors

          5. Willing to give voluntary written informed consent.

        Exclusion Criteria:

          1. Patients with a clinically significant systemic disease, endocrine or metabolic
             abnormalities.

          2. Body Mass Index &gt; 30 (BMI; kg/m2) at screening.

          3. Patients with a uterine (fibroids (diameter greater than or equal to 2CM endometrium),
             endometrial polyps, intrauterine adhesions, uterine malformations), ovaries
             (polycystic ovary, ovarian cysts) or adnexa (hydrosalpinx) abnormalities at screening.

          4. patients with uterine, ovarian surgery treatment

          5. Patients who experienced of severe ovarian hyperstimulation symptoms (OHSS) in
             previous IVF cycles.

          6. Patients who have shown poor response with gonadotropin hormone therapy.

             *At least two of the following three features must be present:

             ① A previous POR(≤3 retrieved oocyte with a conventional stimulation protocol)

             ② An abnormal ovarian reserve test (i.e. AFC &lt; 5 follicles) at screening.

          7. Abnormal metrorrhagia due to unknown reason at screening.

          8. At least one of husband and wife to accept donor sperm or donor eggs or PGD subject

          9. Subjects who are positive for HIV or syphilis at screening.

         10. Significant known psychiatric disorder or who unable to understand the objectives and
             methods, etc. of this clinical trial and unable to comply with the study procedures at
             screening.

         11. Presence of elicit alcohol, smoke or drug abuse habit at screening.

         12. History of hypersensitivity to rhFSH or other pharmaceutical excipients of this drug.

         13. Participation in any other clinical trial after registering for this study or have
             participated in another clinical study within 3 month before randomization in this
             study.

         14. History of tumors of the ovary, breast, uterus, hypothalamus or pituary gland.

         15. More than 3 times previously consecutive unsuccessful in vitro fertilization cycles at
             screening.

         16. Subjects with no clomiphene citrate or gonadotropin treatment within 1 month before
             randomization.

         17. Positive serum pregnancy test at screening.

         18. 14 ± 2 days after the demotion, results of subjects who does not belong to the
             standard (antral follicle size ≥10mm)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>39 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ying Pu Sun</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital of Zhengzhou University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hangzhou Yuyuan Bioscience Technology Co.,Ltd</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310018</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 11, 2018</study_first_submitted>
  <study_first_submitted_qc>April 22, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 24, 2018</study_first_posted>
  <last_update_submitted>April 22, 2018</last_update_submitted>
  <last_update_submitted_qc>April 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>IVF, rhFSH</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
    <mesh_term>Infertility, Female</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

